NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4700
-0.0200 (-1.34%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4900
Open1.5000
Bid1.4700 x 1100
Ask1.4900 x 3100
Day's Range1.4250 - 1.5055
52 Week Range1.1600 - 3.2700
Volume1,458,778
Avg. Volume1,173,416
Market Cap138.981M
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-1.2770
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Benzinga

    The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ):  AbbVie Inc ...

  • GlobeNewswire

    Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection

    Nabriva Therapeutics plc (NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its New Drug Application (NDA) resubmission for marketing approval of CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTIs). In the acknowledgement letter for the resubmitted NDA, the FDA stated that Nabriva’s filing was a complete, class 2 response to the complete response letter the FDA issued on April 30, 2019.

  • Nabriva takes another shot at getting infection drug approved; raising $20M
    American City Business Journals

    Nabriva takes another shot at getting infection drug approved; raising $20M

    The company, which has its U.S. headquarters in King of Prussia, is also planning to raise $20 million in a private stock sale.

  • GlobeNewswire

    Nabriva Therapeutics Announces $20 Million Registered Direct Offering

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering of (i) an aggregate of 13,793,106 ordinary shares and (ii) warrants to purchase up to an aggregate of 13,793,106 ordinary shares. Each ordinary share and accompanying warrant are being sold together at a combined purchase price of $1.45. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • MarketWatch

    Nabriva's stock soars after resubmitting NDA for UTI treatment

    Shares of Nabriva Therapeutics PLC soared 10.5% in premarket trading Friday, after the biotechnology company said it resubmitted its new drug application (NDA) for Contepo, its treatment for complicated urinary tract infections. The NDA was submitted after the Food and Drug Administration said in a complete response letter (CRL) in April that it couldn't approve the previous NDA, citing issues related to facility inspections and manufacturing deficiencies. The NDA was resubmitted based on the outcome of a Type A meeting with the FDA. "We are pleased to have received input from the FDA on the required information to include in the CONTEPO NDA resubmission to address the CRL," said Nabriva Chief Executive Ted Schroeder. The stock has lost 21.8% over the past three months through Thursday, while the iShares Nasdaq Biotechnology ETF has rallied 14.8% and the S&P 500 has gained 7.1%.

  • GlobeNewswire

    Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

    Nabriva Therapeutics plc (NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis. Nabriva anticipates a six-month review period by the FDA.

  • Smart Money Is Buying Nabriva Therapeutics plc (NBRV)
    Insider Monkey

    Smart Money Is Buying Nabriva Therapeutics plc (NBRV)

    Is Nabriva Therapeutics plc (NASDAQ:NBRV) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • Investors Who Bought Nabriva Therapeutics (NASDAQ:NBRV) Shares A Year Ago Are Now Down 11%
    Simply Wall St.

    Investors Who Bought Nabriva Therapeutics (NASDAQ:NBRV) Shares A Year Ago Are Now Down 11%

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • GlobeNewswire

    Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 18,000 ordinary shares of Nabriva Therapeutics as inducements to 4 newly-hired employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The stock options were granted effective November 29, 2019 with an exercise price of $2.02 per share, which is equal to the closing price of Nabriva Therapeutics’s ordinary shares on the date of grant.

  • Benzinga

    Bulls And Bears Of The Week: Nio, Target, Apple and More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included two leaders in computing and a well-known shoe retailer. Much of the market and economic news was overshadowed this week by drama in Washington, D.C. as the impeachment hearings continued on Capitol Hill, though it was hard to see much of an effect on the markets.

  • GlobeNewswire

    Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender Chief Financial Officer and Francesco Lavino Chief Commercial Officer, will provide a company overview and business update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 4:30 p.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

  • Benzinga

    Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

    ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date. Nabriva has a commercial product in lefamulin IV/oral, which was approved by the FDA in August for treating community-acquired bacterial pneumonia, or CABP. The mode of action is through binding to the peptidyl transferase center present in the ribosome of the bacteria, interfering with the interaction of protein production at two key sites — the A site and P site — that inhibit protein production and in turn the growth of bacteria.

  • GlobeNewswire

    Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship

    S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community.

  • GlobeNewswire

    Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    -More than 200 hospital formulary reviews of XENLETA™ scheduled before the end of the year- -Approximately 50% of all covered lives have outpatient formulary access to XENLETA-.

  • GlobeNewswire

    Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, November 12, 2019. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com.

  • GlobeNewswire

    Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it will present data on the pooled results from completed Phase 3 trials of XENLETA™ (lefamulin) at the CHEST Annual Meeting 2019, to be held October 19-23 in New Orleans. XENLETA is a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of community-acquired bacterial pneumonia (CABP) in adults and is now commercially available in the United States. “The clinical community desperately needs new classes of antibiotics with different mechanisms of action that have targeted, potent antimicrobial activity and improved safety and tolerability over existing therapies,” said Jennifer Schranz, M.D., Chief Medical Officer of Nabriva Therapeutics.

  • 3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020
    TipRanks

    3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020

    In any industry, there are always deals that are too good to be true and unfortunately, they usually are. The best thing to do before any kind of investment is to educate yourself before you make any hasty decisions. Being extra cautious could be an excellent idea.When it comes to the stock market though, “playing it safe” doesn’t always pay off and putting your money on a seemingly ‘sure bet’ that most big players are investing in, might not get you the results you are actually looking for.When you take a deeper look, you’ll notice that there are actually incredible opportunities in “smaller” and less heard of biotech stocks that can bring you closer to the sweet payday.Using TipRanks’ Stock Screener, we’ve highlighted 3 ultra-promising biotechs that are showing upside of nearly 300% and above.Gamida Cell (GMDA) Gamida Cell is a clinical-stage biopharmaceutical company that is creating and developing cell therapies for different types of cancers. The company has its own proprietary nicotinamide-based (or NAM based) cell expansion technology which is pretty much its “trade secret." NAM-based cell expansion takes the natural state of cancer cells and modifies them so that they are no longer harmful to the body.Gamida is hoping to bank on the success of its frontrunner drug ‘omidubicel’ which is expected to be a life-saving stem cell transplant solution for patients with high-risk blood cancers and bone marrow failure disorders. Omidubicel is currently in Phase 3 of its clinical trials.4-star JMP analyst Jason N. Bulter sees the Phase 3 results for omidubicel in 1H20 “as the primary value driver for the stock” and identifies “potential for success based on positive Phase 2 results.” And that’s good enough reason for Bulter to rate the stock an Outperform along with $16 price target. If the price target is reached within 12 months, that would provide a 12-month return of nearly 261%."Our..price target is derived through an NPV analysis of omidubicel sales, for which we project U.S. sales of ~$580MM by 2027 and assign a 75% probability of approval.” the analyst explained.Overall, we can see from TipRanks that Gamida has a “Strong Buy” consensus rating. In the last three months, the stock has received 22 buy ratings and seven hold ratings. Based on these ratings, the average $175 price target on X stock translates into upside of over 10% from the current share price.Gamida stock has a resounding “yes” on Wall Street. TipRanks analytics show that out of three analysts polled in the past 3 months, all three are bullish. The price target of $17.67 shows a potential upside of about nearly 300% from where the stock is currently trading. (See Gamida stock analysis on TipRanks)Nabriva Therapeutics (NBRV) Similarly to GMDA, Nabriva Therapeutics is a company that also has 2 premiere projects in the works and has a lot of promising developments going on. Nabriva's lead drug XENLETA, which treats patients with community-acquired bacterial pneumonia (CABP), recently won FDA approval and is being distributed in the U.S. since August. Nabriva also recently acquired Zvante Therapeutics and added CONTEPO to its portfolio; an injection for the treatment of complicated urinary tract infections. In contrast to XENLETA, however, CONTEPO has yet to gain FDA approval.Northland analyst Carl Brynes is forecasting "peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms." With a market cap of only $130.58 million, the analyst sees huge upside for NBRV stock, as he reiterates an Outperform rating and $12.50 price target. (To watch Brynes' track record, click here)Wedbush analyst Robert Driscoll added, "We see XENLETA’s profile as well suited for the treatment of CABP, given its favorable safety and efficacy profile, a narrow but CABP-targeted spectrum, and flexible IV to oral/oral dosing. Importantly, two Ph 3 studies have demonstrated efficacy with a short treatment course of 5-7 days, which we note aligns with antibiotic stewardship principles. With recent favorable changes to the reimbursement landscape and a clear plan in place for lefamulin commercialization, plus clarification around second asset CONTEPO NDA resubmission timelines, we believe NBRV shares are currently undervalued."All in all, the drug maker is without question a Wall Street favorite, considering TipRanks analytics indicate NBRV as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of nearly 390%, the stock's consensus target price stands at $8.70. (See Nabriva stock analysis on TipRanks)PhaseBio Pharmacuticals (PHAS)Rounding out our list is PhaseBio Pharmacuticals, a clinical-stage biopharmaceutical, developing treatments for orphan diseases with cardiopulmonary indications. PhaseBio's stake in the race is PB2452; medication that the company hopes will undo the negative effects of the antiplatelet drug ticagrelor. The company also has a really good second offering in PB1046; its treatment of PAH (pulmonary arterial hypertension), which creates high blood pressure in the arteries of the lungs.The company recently announced that it completed the Phase 2a clinical trial of PB2452 on healthy elderly patients and that the results have been consistent to its former Phase 1 study with younger, healthy patients. This is good news for PHAS and shows that the company is right on track with its clinical trial advances.William Blair analyst Matt Phipps believes “the completion of the Phase 2a study continues a pattern of excellent execution from company management, and we look forward to the full data presentation at an upcoming medical conference and initiation of pivotal trials in the coming months." The analyst added that “the base case...for PB2452, which assumes a peak penetration for ticagrelor of 40% of the addressable market, results in a risk-adjusted net present value of roughly $16 per share.”With that in mind, it's not surprising why Phipps reiterated an Outperform rating on PHAS stock, while boosting his price target to $7.00 (from $5.00).How does Phipps' bullish forecast echo against the word of the Street? Quite positively, it seems, as TipRanks analytics exhibit PHAS as a Strong Buy. Based on 5 analysts polled in the last 3 months, all 5 rate the stock a "buy." Meanwhile, the 12-month average price target stands at $18.33, marking nearly 340% upside from where the stock is currently trading. (See PhaseBio stock analysis on TipRanks)

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire

    Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association

    DUBLIN, Ireland, Sept. 27, 2019 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative.

  • GlobeNewswire

    Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019

    DUBLIN, Ireland, Sept. 26, 2019 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative.

  • GlobeNewswire

    Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 1:50 p.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

  • Is Nabriva Therapeutics (NASDAQ:NBRV) Using Too Much Debt?
    Simply Wall St.

    Is Nabriva Therapeutics (NASDAQ:NBRV) Using Too Much Debt?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • GlobeNewswire

    Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formulations of XENLETA™ (lefamulin) are now available in the U.S. through major specialty distributors. XENLETA was approved by the U.S. Food and Drug Administration (FDA) on August 19, 2019 for the treatment of adults with community-acquired bacterial pneumonia (CABP). “The lack of innovative treatment options for CABP over the past two decades has resulted in increasing resistance in the most common bacteria causing CABP to multiple classes of antibiotics,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.